Catheter Precision gains UK approval for LockeT product, partners with HC21.

• Catheter Precision's LockeT suture retention device gets UK registration and approval. • CE Mark for European approval and distribution was received in May 2025. • HC21, a UK-based distributor, will distribute LockeT in the UK. • HC21 has an annual revenue of €180 million and 500+ employees across the UK and Ireland.

Catheter Precision, Inc. (VTAK - NYSE/American), a U.S.-based medical device company focused on developing advanced products for the cardiac electrophysiology market, has announced the registration and approval of its LockeT suture retention device in the United Kingdom. This approval follows the device's CE Mark certification in May 2025, which was the final regulatory step needed for commercialization in the UK.

The LockeT device is designed to enhance patient comfort, facilitate earlier discharge after cardiac procedures, and support the National Health Service's (NHS) efforts to reduce waiting lists. The company has partnered with HC21, a major UK-based distributor with €180 million in annual revenue and over 500 employees across the UK and Ireland, to distribute the product through HC21's established network.

HC21's extensive presence and operational synergies with Catheter Precision make this partnership particularly strategic. The LockeT device addresses a specific clinical need in cardiac electrophysiology procedures, with the potential to improve patient outcomes while also offering benefits to the healthcare system. The UK market, with approximately 100,000 cardiac device procedures annually, represents a significant opportunity for specialized devices that can enhance procedural efficiency and patient throughput.

Fatih Ayoglu, Sales Manager EMEA & APAC for Catheter Precision, expressed pride in the UK approval, noting that "LockeT’s intuitive design and ease of deployment not only enhance patient comfort and recovery but also enable earlier discharge following cardiac procedures. This directly supports NHS efforts to reduce waiting lists by freeing up hospital capacity and accelerating patient throughput."

The UK registration completes Catheter Precision's regulatory requirements for commercialization in this key European market, expanding its commercial opportunities in the competitive cardiac electrophysiology market.

References:
[1] https://www.stocktitan.net/news/VTAK/catheter-precision-receives-approval-for-locke-t-in-the-united-97wcp86b1sjk.html
[2] https://www.morningstar.com/news/globe-newswire/9513896/catheter-precision-receives-approval-for-locket-in-the-united-kingdom